{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:09:37Z","timestamp":1790932177752,"version":"4.1.0"},"reference-count":258,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health, NIH","doi-asserted-by":"publisher","award":["R01 EY013431"],"award-info":[{"award-number":["R01 EY013431"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health, NIH","doi-asserted-by":"publisher","award":["EY031377"],"award-info":[{"award-number":["EY031377"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>This review provides comprehensive information about the advances in gene therapy in the anterior segment of the eye, including cornea, conjunctiva, lacrimal gland, and trabecular meshwork. We discuss gene delivery systems, including viral and non-viral vectors as well as gene editing techniques, mainly CRISPR-Cas9, and epigenetic treatments, including antisense and siRNA therapeutics. We also provide a detailed analysis of various anterior segment diseases where gene therapy has been tested with corresponding outcomes. Disease conditions include corneal and conjunctival fibrosis and scarring, corneal epithelial wound healing, corneal graft survival, corneal neovascularization, genetic corneal dystrophies, herpetic keratitis, glaucoma, dry eye disease, and other ocular surface diseases. Although most of the analyzed results on the use and validity of gene therapy at the ocular surface have been obtained in vitro or using animal models, we also discuss the available human studies. Gene therapy approaches are currently considered very promising as emerging future treatments of various diseases, and this field is rapidly expanding.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1566523221666210423084233","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T04:42:32Z","timestamp":1619498552000},"page":"104-131","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Gene Therapy in the Anterior Eye Segment"],"prefix":"10.2174","volume":"22","author":[{"given":"Cynthia","family":"Amador","sequence":"first","affiliation":[{"name":"Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars- Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Shah","sequence":"additional","affiliation":[{"name":"Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars- Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ghiam","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, New York State\/American Program of Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei A.","family":"Kramerov","sequence":"additional","affiliation":[{"name":"Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars- Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-5319","authenticated-orcid":true,"given":"Alexander V.","family":"Ljubimov","sequence":"additional","affiliation":[{"name":"Eye Program, Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars- Sinai Medical Center, Los Angeles, CA, USA | Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"Anguela X.M.","year":"2019","unstructured":"Anguela X.M.; High K.A.; Entering the modern era of gene therapy. Annu Rev Med 2019,70,273-288","journal-title":"Annu Rev Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","volume":"525","author":"Wirth T.","year":"2013","unstructured":"Wirth T.; Parker N.; Yl&#xE4;-Herttuala S.; History of gene therapy. Gene 2013,525(2),162-169","journal-title":"Gene"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"Dunbar C.E.","year":"2018","unstructured":"Dunbar C.E.; High K.A.; Joung J.K.; Kohn D.B.; Ozawa K.; Sadelain M.; Gene therapy comes of age. Science 2018,359(6372),eaan4672","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"High K.A.","year":"2019","unstructured":"High K.A.; Roncarolo M.G.; Gene Therapy. N Engl J Med 2019,381(5),455-464","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1006\/mthe.2000.0080","volume":"1","author":"Bennett J.","year":"2000","unstructured":"Bennett J.; Maguire A.M.; Gene therapy for ocular disease. Mol Ther 2000,1(6),501-505","journal-title":"Mol Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0014-4835(03)00030-7","volume":"76","author":"Borr&#xE1;s T.","year":"2003","unstructured":"Borr&#xE1;s T.; Recent developments in ocular gene therapy. Exp Eye Res 2003,76(6),643-652","journal-title":"Exp Eye Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/hum.2019.026","volume":"30","author":"Di Iorio E.","year":"2019","unstructured":"Di Iorio E.; Barbaro V.; Alvisi G.; Trevisan M.; Ferrari S.; Masi G.; Nespeca P.; Ghassabian H.; Ponzin D.; Pal&#xF9; G.; New frontiers of corneal gene therapy. Hum Gene Ther 2019,30(8),923-945","journal-title":"Hum Gene Ther"},{"key":"ref=8","first-page":"1037","volume":"60","author":"Ljubimov A.V.","year":"2019","unstructured":"Ljubimov A.V.; Overview of gene therapy in anterior segment. Invest Ophthalmol Vis Sci 2019,60,1037","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"108361","DOI":"10.1016\/j.exer.2020.108361","volume":"202","author":"Mohan R.R.","year":"2021","unstructured":"Mohan R.R.; Martin L.M.; Sinha N.R.; Novel insights into gene therapy in the cornea. Exp Eye Res 2021,202,108361","journal-title":"Exp Eye Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"Shirley J.L.","year":"2020","unstructured":"Shirley J.L.; de Jong Y.P.; Terhorst C.; Herzog R.W.; Immune responses to viral gene therapy vectors. Mol Ther 2020,28(3),709-722","journal-title":"Mol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1002\/jgm.496","volume":"6","author":"Volpers C.","year":"2004","unstructured":"Volpers C.; Kochanek S.; Adenoviral vectors for gene transfer and therapy. J Gene Med 2004,6(Suppl. 1),S164-S171","journal-title":"J Gene Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jtos.2012.10.004","volume":"11","author":"Mohan R.R.","year":"2013","unstructured":"Mohan R.R.; Rodier J.T.; Sharma A.; Corneal gene therapy: Basic science and translational perspective. Ocul Surf 2013,11(3),150-164","journal-title":"Ocul Surf"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1167\/iovs.09-4569","volume":"51","author":"Saghizadeh M.","year":"2010","unstructured":"Saghizadeh M.; Kramerov A.A.; Yu F.S.; Castro M.G.; Ljubimov A.V.; Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. Invest Ophthalmol Vis Sci 2010,51(4),1970-1980","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/104303401750270959","volume":"12","author":"Lai C.M.","year":"2001","unstructured":"Lai C.M.; Brankov M.; Zaknich T.; Lai Y.K.; Shen W.Y.; Constable I.J.; Kovesdi I.; Rakoczy P.E.; Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001,12(10),1299-1310","journal-title":"Hum Gene Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1080\/02713683.2017.1344714","volume":"42","author":"Kaufmann C.","year":"2017","unstructured":"Kaufmann C.; Mortimer L.A.; Brereton H.M.; Irani Y.D.; Parker D.G.; Anson D.S.; Bachmann L.M.; Williams K.A.; Interleukin-10 gene transfer in rat limbal transplantation. Curr Eye Res 2017,42(11),1426-1434","journal-title":"Curr Eye Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","volume":"11","author":"Bessis N.","year":"2004","unstructured":"Bessis N.; GarciaCozar F.J.; Boissier M.C.; Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther 2004,11(Suppl. 1),S10-S17","journal-title":"Gene Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1089\/10430349950016807","volume":"10","author":"Kochanek S.","year":"1999","unstructured":"Kochanek S.; High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 1999,10(15),2451-2459","journal-title":"Hum Gene Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"Boutin S.","year":"2010","unstructured":"Boutin S.; Monteilhet V.; Veron P.; Leborgne C.; Benveniste O.; Montus M.F.; Masurier C.; Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther 2010,21(6),704-712","journal-title":"Hum Gene Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/rmv.1762","volume":"23","author":"Hareendran S.","year":"2013","unstructured":"Hareendran S.; Balakrishnan B.; Sen D.; Kumar S.; Srivastava A.; Jayandharan G.R.; Adeno-associated virus (AAV) vectors in gene therapy: Immune challenges and strategies to circumvent them. Rev Med Virol 2013,23(6),399-413","journal-title":"Rev Med Virol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"Mingozzi F.","year":"2013","unstructured":"Mingozzi F.; High K.A.; Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood 2013,122(1),23-36","journal-title":"Blood"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","volume":"17","author":"Martino A.T.","year":"2019","unstructured":"Martino A.T.; Markusic D.M.; Immune response mechanisms against AAV vectors in animal models. Mol Ther Methods Clin Dev 2019,17,198-208","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"Naso M.F.","year":"2017","unstructured":"Naso M.F.; Tomkowicz B.; Perry W.L.; Strohl W.R.; Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 2017,31(4),317-334","journal-title":"BioDrugs"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e26432","DOI":"10.1371\/journal.pone.0026432","volume":"6","author":"Mohan R.R.","year":"2011","unstructured":"Mohan R.R.; Tovey J.C.; Sharma A.; Schultz G.S.; Cowden J.W.; Tandon A.; Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One 2011,6(10),e26432","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.exer.2010.06.020","volume":"91","author":"Sharma A.","year":"2010","unstructured":"Sharma A.; Tovey J.C.; Ghosh A.; Mohan R.R.; AAV serotype influences gene transfer in corneal stroma in vivo. Exp Eye Res 2010,91(3),440-448","journal-title":"Exp Eye Res"},{"key":"ref=25","first-page":"2087","volume":"14","author":"Liu J.","year":"2008","unstructured":"Liu J.; Saghizadeh M.; Tuli S.S.; Kramerov A.A.; Lewin A.S.; Bloom D.C.; Hauswirth W.W.; Castro M.G.; Schultz G.S.; Ljubimov A.V.; Different tropism of adenoviruses and adeno-associated viruses to corneal cells: Implications for corneal gene therapy. Mol Vis 2008,14,2087-2096","journal-title":"Mol Vis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41434-018-0035-6","volume":"25","author":"Song L.","year":"2018","unstructured":"Song L.; Llanga T.; Conatser L.M.; Zaric V.; Gilger B.C.; Hirsch M.L.; Serotype survey of AAV gene delivery via subconjunctival injection in mice. Gene Ther 2018,25(6),402-414","journal-title":"Gene Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/pharmaceutics12080767","volume":"12","author":"Bastola P.","year":"2020","unstructured":"Bastola P.; Song L.; Gilger B.C.; Hirsch M.L.; Adeno-associated virus mediated gene therapy for corneal diseases. Pharmaceutics 2020,12(8),767","journal-title":"Pharmaceutics"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.1167\/iovs.12-10658","volume":"53","author":"Tarallo V.","year":"2012","unstructured":"Tarallo V.; Bogdanovich S.; Hirano Y.; Tudisco L.; Zentilin L.; Giacca M.; Ambati J.; De Falco S.; Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer. Invest Ophthalmol Vis Sci 2012,53(13),7989-7996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"Saint-Geniez M.","year":"2008","unstructured":"Saint-Geniez M.; Maharaj A.S.; Walshe T.E.; Tucker B.A.; Sekiyama E.; Kurihara T.; Darland D.C.; Young M.J.; D\u2019Amore P.A.; Endogenous VEGF is required for visual function: Evidence for a survival role on m&#xFC;ller cells and photoreceptors. PLoS One 2008,3(11),e3554","journal-title":"PLoS One"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtn.2017.12.019","volume":"10","author":"Lu Y.","year":"2018","unstructured":"Lu Y.; Tai P.W.L.; Ai J.; Gessler D.J.; Su Q.; Yao X.; Zheng Q.; Zamore P.D.; Xu X.; Gao G.; Transcriptome profiling of neovascularized corneas reveals miR-204 as a multi-target biotherapy deliverable by rAAVs. Mol Ther Nucleic Acids 2018,10,349-360","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"17840","DOI":"10.1038\/s41598-017-18002-9","volume":"7","author":"Hirsch M.L.","year":"2017","unstructured":"Hirsch M.L.; Conatser L.M.; Smith S.M.; Salmon J.H.; Wu J.; Buglak N.E.; Davis R.; Gilger B.C.; AAV vector-meditated expression of HLA-G reduces injury-induced corneal vascularization, immune cell infiltration, and fibrosis. Sci Rep 2017,7(1),17840","journal-title":"Sci Rep"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/156652309787354621","volume":"9","author":"Parker D.G.","year":"2009","unstructured":"Parker D.G.; Brereton H.M.; Coster D.J.; Williams K.A.; The potential of viral vector-mediated gene transfer to prolong corneal allograft survival. Curr Gene Ther 2009,9(1),33-44","journal-title":"Curr Gene Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"22131","DOI":"10.1038\/srep22131","volume":"6","author":"Vance M.","year":"2016","unstructured":"Vance M.; Llanga T.; Bennett W.; Woodard K.; Murlidharan G.; Chungfat N.; Asokan A.; Gilger B.; Kurtzberg J.; Samulski R.J.; Hirsch M.L.; AAV gene therapy for MPS1-associated corneal blindness. Sci Rep 2016,6,22131","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e0172928","DOI":"10.1371\/journal.pone.0172928","volume":"12","author":"Gupta S.","year":"2017","unstructured":"Gupta S.; Rodier J.T.; Sharma A.; Giuliano E.A.; Sinha P.R.; Hesemann N.P.; Ghosh A.; Mohan R.R.; Targeted AAV5-Smad7 gene therapy inhibits corneal scarring in vivo. PLoS One 2017,12(3),e0172928","journal-title":"PLoS One"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.trim.2013.04.007","volume":"28","author":"Zhou L.","year":"2013","unstructured":"Zhou L.; Zhu X.; Tan J.; Wang J.; Xing Y.; Effect of recombinant adeno-associated virus mediated transforming growth factor-&#x3B2;1 on corneal allograft survival after high-risk penetrating keratoplasty. Transpl Immunol 2013,28(4),164-169","journal-title":"Transpl Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/pharmaceutics12040335","volume":"12","author":"Alvarez-Rivera F.","year":"2020","unstructured":"Alvarez-Rivera F.; Rey-Rico A.; Venkatesan J.K.; Diaz-Gomez L.; Cucchiarini M.; Concheiro A.; Alvarez-Lorenzo C.; Controlled release of rAAV vectors from APMA-functionalized contact lenses for corneal gene therapy. Pharmaceutics 2020,12(4),335","journal-title":"Pharmaceutics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12033-007-0010-8","volume":"36","author":"Cockrell A.S.","year":"2007","unstructured":"Cockrell A.S.; Kafri T.; Gene delivery by lentivirus vectors. Mol Biotechnol 2007,36(3),184-204","journal-title":"Mol Biotechnol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1042\/BJ20120146","volume":"443","author":"Sakuma T.","year":"2012","unstructured":"Sakuma T.; Barry M.A.; Ikeda Y.; Lentiviral vectors: Basic to translational. Biochem J 2012,443(3),603-618","journal-title":"Biochem J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1089\/hum.2013.079","volume":"25","author":"Parker M.","year":"2014","unstructured":"Parker M.; Bellec J.; McFarland T.; Scripps V.; Appukuttan B.; Hartzell M.; Yeager A.; Hady T.; Mitrophanous K.A.; Stout T.; Ellis S.; Suppression of neovascularization of donor corneas by transduction with equine infectious anemia virus-based lentiviral vectors expressing endostatin and angiostatin. Hum Gene Ther 2014,25(5),408-418","journal-title":"Hum Gene Ther"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3760\/cma.j.issn.0366-6999.20123672","volume":"126","author":"Wang T.","year":"2013","unstructured":"Wang T.; Zhou X.T.; Yu Y.; Zhu J.Y.; Dai J.H.; Qu X.M.; Le Q.H.; Chu R.Y.; Inhibition of corneal fibrosis by Smad7 in rats after photorefractive keratectomy. Chin Med J (Engl) 2013,126(8),1445-1450","journal-title":"Chin Med J (Engl)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1590\/S0004-27492010000500012","volume":"73","author":"Oliveira L.A.","year":"2010","unstructured":"Oliveira L.A.; Kim C.; Sousa L.B.; Schwab I.R.; Rosenblatt M.I.; Gene transfer to primary corneal epithelial cells with an integrating lentiviral vector. Arq Bras Oftalmol 2010,73(5),447-453","journal-title":"Arq Bras Oftalmol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"GE01","DOI":"10.7860\/JCDR\/2015\/10443.5394","volume":"9","author":"Ramamoorth M.","year":"2015","unstructured":"Ramamoorth M.; Narvekar A.; Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015,9(1),GE01-GE06","journal-title":"J Clin Diagn Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/genes8020065","volume":"8","author":"Hardee C.L.","year":"2017","unstructured":"Hardee C.L.; Ar&#xE9;valo-Soliz L.M.; Hornstein B.D.; Zechiedrich L.; Advances in non-viral DNA vectors for gene therapy. Genes (Basel) 2017,8(2),65","journal-title":"Genes (Basel)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.exer.2011.07.001","volume":"95","author":"Kampik D.","year":"2012","unstructured":"Kampik D.; Ali R.R.; Larkin D.F.; Experimental gene transfer to the corneal endothelium. Exp Eye Res 2012,95(1),54-59","journal-title":"Exp Eye Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2003.11.008","volume":"9","author":"Reyes-Sandoval A.","year":"2004","unstructured":"Reyes-Sandoval A.; Ertl H.C.; CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol Ther 2004,9(2),249-261","journal-title":"Mol Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"12631","DOI":"10.1073\/pnas.95.21.12631","volume":"95","author":"Krieg A.M.","year":"1998","unstructured":"Krieg A.M.; Wu T.; Weeratna R.; Efler S.M.; Love-Homan L.; Yang L.; Yi A.K.; Short D.; Davis H.L.; Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998,95(21),12631-12636","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1006\/mthe.2000.0036","volume":"1","author":"Yew N.S.","year":"2000","unstructured":"Yew N.S.; Zhao H.; Wu I.H.; Song A.; Tousignant J.D.; Przybylska M.; Cheng S.H.; Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 2000,1(3),255-262","journal-title":"Mol Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s11095-008-9558-7","volume":"25","author":"de Wolf H.K.","year":"2008","unstructured":"de Wolf H.K.; Johansson N.; Thong A.T.; Snel C.J.; Mastrobattista E.; Hennink W.E.; Storm G.; Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes. Pharm Res 2008,25(7),1654-1662","journal-title":"Pharm Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5487\/TR.2019.35.3.287","volume":"35","author":"Lee H.","year":"2019","unstructured":"Lee H.; Park K.; In vitro cytotoxicity of zinc oxide nanoparticles in cultured Statens Serum institut rabbit cornea cells. Toxicol Res 2019,35(3),287-294","journal-title":"Toxicol Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e66434","DOI":"10.1371\/journal.pone.0066434","volume":"8","author":"Tandon A.","year":"2013","unstructured":"Tandon A.; Sharma A.; Rodier J.T.; Klibanov A.M.; Rieger F.G.; Mohan R.R.; BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS One 2013,8(6),e66434","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.3390\/molecules24162929","volume":"24","author":"Masse F.","year":"2019","unstructured":"Masse F.; Desjardins P.; Ouellette M.; Couture C.; Omar M.M.; Pernet V.; Gu&#xE9;rin S.; Boisselier E.; Synthesis of ultrastable gold nanoparticles as a new drug delivery system. Molecules 2019,24(16),2929","journal-title":"Molecules"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"R182","DOI":"10.1088\/0022-3727\/36\/13\/202","volume":"36","author":"Tartaj P.","year":"2003","unstructured":"Tartaj P.; Morales M.; Veintemillas-Verdaguer S.; Gonz&#xE1;lez-Carre&#xF1;o T.; Serna C.J.; The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 2003,36,R182-R197","journal-title":"J Phys D Appl Phys"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7205\/MILMED-D-15-00151","volume":"181","author":"Cornell L.E.","year":"2016","unstructured":"Cornell L.E.; Wehmeyer J.L.; Johnson A.J.; Desilva M.N.; Zamora D.O.; Magnetic nanoparticles as a potential vehicle for corneal endothelium repair. Mil Med 2016,181(5)(Suppl.),232-239","journal-title":"Mil Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1167\/iovs.18-26001","volume":"60","author":"Xia X.","year":"2019","unstructured":"Xia X.; Atkins M.; Dalal R.; Kuzmenko O.; Chang K.C.; Sun C.B.; Benatti C.A.; Rak D.J.; Nahmou M.; Kunzevitzky N.J.; Goldberg J.L.; Magnetic human corneal endothelial cell transplant: Delivery, retention, and short-term efficacy. Invest Ophthalmol Vis Sci 2019,60(7),2438-2448","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.nano.2014.12.002","volume":"11","author":"Moysidis S.N.","year":"2015","unstructured":"Moysidis S.N.; Alvarez-Delfin K.; Peschansky V.J.; Salero E.; Weisman A.D.; Bartakova A.; Raffa G.A.; Merkhofer R.M.; Kador K.E.; Kunzevitzky N.J.; Goldberg J.L.; Magnetic field-guided cell delivery with nanoparticle-loaded human corneal endothelial cells. Nanomedicine (Lond) 2015,11(3),499-509","journal-title":"Nanomedicine (Lond)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/jgm.1093","volume":"9","author":"Tong Y.C.","year":"2007","unstructured":"Tong Y.C.; Chang S.F.; Liu C.Y.; Kao W.W.; Huang C.H.; Liaw J.; Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J Gene Med 2007,9(11),956-966","journal-title":"J Gene Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1208\/s12249-014-0159-y","volume":"15","author":"Cholkar K.","year":"2014","unstructured":"Cholkar K.; Hariharan S.; Gunda S.; Mitra A.K.; Optimization of dexamethasone mixed nanomicellar formulation. AAPS PharmSciTech 2014,15(6),1454-1467","journal-title":"AAPS PharmSciTech"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"107697","DOI":"10.1016\/j.exer.2019.107697","volume":"185","author":"Luis de Red&#xED;n I.","year":"2019","unstructured":"Luis de Red&#xED;n I.; Boiero C.; Recalde S.; Ag&#xFC;eros M.; Allemandi D.; Llabot J.M.; Garc&#xED;a-Layana A.; Irache J.M.; In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. Exp Eye Res 2019,185,107697","journal-title":"Exp Eye Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.1016\/j.biomaterials.2012.06.079","volume":"33","author":"Jiang M.","year":"2012","unstructured":"Jiang M.; Gan L.; Zhu C.; Dong Y.; Liu J.; Gan Y.; Cationic core-shell liponanoparticles for ocular gene delivery. Biomaterials 2012,33(30),7621-7630","journal-title":"Biomaterials"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.addr.2017.06.002","volume":"113","author":"Ljubimova J.Y.","year":"2017","unstructured":"Ljubimova J.Y.; Sun T.; Mashouf L.; Ljubimov A.V.; Israel L.L.; Ljubimov V.A.; Falahatian V.; Holler E.; Covalent nano delivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev 2017,113,177-200","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.addr.2020.07.020","volume":"156","author":"Kope&#x10D;ek J.","year":"2020","unstructured":"Kope&#x10D;ek J.; Yang J.; Polymer nanomedicines. Adv Drug Deliv Rev 2020,156,40-64","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jconrel.2010.06.006","volume":"147","author":"Tong Y.C.","year":"2010","unstructured":"Tong Y.C.; Chang S.F.; Kao W.W.; Liu C.Y.; Liaw J.; Polymeric micelle gene delivery of bcl-xL via eye drop reduced corneal apoptosis following epithelial debridement. J Control Release 2010,147(1),76-83","journal-title":"J Control Release"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nano.2014.05.009","volume":"11","author":"Kalomiraki M.","year":"2015","unstructured":"Kalomiraki M.; Thermos K.; Chaniotakis N.A.; Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine 2015,11,1-12","journal-title":"Int J Nanomedicine"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.nano.2011.08.018","volume":"8","author":"Holden C.A.","year":"2012","unstructured":"Holden C.A.; Tyagi P.; Thakur A.; Kadam R.; Jadhav G.; Kompella U.B.; Yang H.; Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine (Lond) 2012,8(5),776-783","journal-title":"Nanomedicine (Lond)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","volume":"125","author":"Soiberman U.","year":"2017","unstructured":"Soiberman U.; Kambhampati S.P.; Wu T.; Mishra M.K.; Oh Y.; Sharma R.; Wang J.; Al Towerki A.E.; Yiu S.; Stark W.J.; Kannan R.M.; Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation. Biomaterials 2017,125,38-53","journal-title":"Biomaterials"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/10717544.2019.1667455","volume":"26","author":"Yang X.","year":"2019","unstructured":"Yang X.; Wang L.; Li L.; Han M.; Tang S.; Wang T.; Han J.; He X.; He X.; Wang A.; Sun K.; A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. Drug Deliv 2019,26(1),989-1001","journal-title":"Drug Deliv"},{"key":"ref=67","author":"Maloy S.R.","year":"2013","unstructured":"Maloy S.R.; Hughes K.T.; Brenner\u2019s encyclopedia of genetics 2013","journal-title":"Brenner\u2019s encyclopedia of genetics"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4049\/jimmunol.175.1.509","volume":"175","author":"Kim B.","year":"2005","unstructured":"Kim B.; Lee S.; Suvas S.; Rouse B.T.; Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects. J Immunol 2005,175(1),509-516","journal-title":"J Immunol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1167\/iovs.06-0853","volume":"48","author":"Jani P.D.","year":"2007","unstructured":"Jani P.D.; Singh N.; Jenkins C.; Raghava S.; Mo Y.; Amin S.; Kompella U.B.; Ambati B.K.; Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007,48(5),2030-2036","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/gt.2010.159","volume":"18","author":"Galiacy S.D.","year":"2011","unstructured":"Galiacy S.D.; Fourni&#xE9; P.; Massoudi D.; Anc&#xE8;le E.; Quintyn J.C.; Erraud A.; Raymond-Letron I.; Rolling F.; Malecaze F.; Matrix metalloproteinase 14 overexpression reduces corneal scarring. Gene Ther 2011,18(5),462-468","journal-title":"Gene Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000246577","volume":"43","author":"He Z.","year":"2010","unstructured":"He Z.; Pipparelli A.; Manissolle C.; Acquart S.; Garraud O.; Gain P.; Thuret G.; Ex vivo gene electrotransfer to the endothelium of organ cultured human corneas. Ophthalmic Res 2010,43(1),43-55","journal-title":"Ophthalmic Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/jgm.231","volume":"4","author":"Blair-Parks K.","year":"2002","unstructured":"Blair-Parks K.; Weston B.C.; Dean D.A.; High-level gene transfer to the cornea using electroporation. J Gene Med 2002,4(1),92-100","journal-title":"J Gene Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/1566523216666160331130040","volume":"16","author":"Rosazza C.","year":"2016","unstructured":"Rosazza C.; Meglic S.H.; Zumbusch A.; Rols M.P.; Miklavcic D.; Gene electrotransfer: A mechanistic perspective. Curr Gene Ther 2016,16(2),98-129","journal-title":"Curr Gene Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000072143","volume":"35","author":"Yu W.Z.","year":"2003","unstructured":"Yu W.Z.; Li X.X.; She H.C.; He P.Y.; Dong J.Q.; Rui M.; Ma D.L.; Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 2003,35(5),239-246","journal-title":"Ophthalmic Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/sj.gt.3302337","volume":"11","author":"Wells D.J.","year":"2004","unstructured":"Wells D.J.; Gene therapy progress and prospects: Electroporation and other physical methods. Gene Ther 2004,11(18),1363-1369","journal-title":"Gene Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.survophthal.2017.10.006","volume":"63","author":"Liu S.","year":"2018","unstructured":"Liu S.; Romano V.; Steger B.; Kaye S.B.; Hamill K.J.; Willoughby C.E.; Gene-based antiangiogenic applications for corneal neovascularization. Surv Ophthalmol 2018,63(2),193-213","journal-title":"Surv Ophthalmol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/108729003321629647","volume":"13","author":"Berdugo M.","year":"2003","unstructured":"Berdugo M.; Valamanesh F.; Andrieu C.; Klein C.; Benezra D.; Courtois Y.; Behar-Cohen F.; Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev 2003,13(2),107-114","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1248\/bpb.b15-00932","volume":"39","author":"Sekijima H.","year":"2016","unstructured":"Sekijima H.; Ehara J.; Hanabata Y.; Suzuki T.; Kimura S.; Lee V.H.; Morimoto Y.; Ueda H.; Characterization of ocular iontophoretic drug transport of ionic and non-ionic compounds in isolated rabbit cornea and conjunctiva. Biol Pharm Bull 2016,39(6),959-968","journal-title":"Biol Pharm Bull"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"3720517","DOI":"10.1155\/2016\/3720517","volume":"2016","author":"Vinciguerra P.","year":"2016","unstructured":"Vinciguerra P.; Romano V.; Rosetta P.; Legrottaglie E.F.; Kubrak-Kisza M.; Azzolini C.; Vinciguerra R.; Iontophoresis-assisted corneal collagen cross-linking with epithelial debridement: Preliminary results. BioMed Res Int 2016,2016,3720517","journal-title":"BioMed Res Int"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"53119","DOI":"10.3791\/53119","volume":"105","author":"Bouheraoua N.","year":"2015","unstructured":"Bouheraoua N.; Jouve L.; Borderie V.; Laroche L.; Three different protocols of corneal collagen crosslinking in keratoconus: Conventional, accelerated and iontophoresis. J Vis Exp 2015,105(105),53119","journal-title":"J Vis Exp"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/aos.12235","volume":"92","author":"Bikbova G.","year":"2014","unstructured":"Bikbova G.; Bikbov M.; Transepithelial corneal collagen cross-linking by iontophoresis of riboflavin. Acta Ophthalmol 2014,92(1),e30-e34","journal-title":"Acta Ophthalmol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00417-001-0411-5","volume":"240","author":"Zhang E.P.","year":"2002","unstructured":"Zhang E.P.; Muller A.; Schulte F.; K&#xF6;nig M.S.; Sack F.; Junghans C.; Wittig B.; Hoffmann F.; Minimizing side effects of ballistic gene transfer into the murine corneal epithelium. Graefes Arch Clin Exp Ophthalmol 2002,240(2),114-119","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/01.ico.0000153561.89902.57","volume":"24","author":"Zagon I.S.","year":"2005","unstructured":"Zagon I.S.; Sassani J.W.; Verderame M.F.; McLaughlin P.J.; Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea 2005,24(5),614-619","journal-title":"Cornea"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/archopht.124.11.1620","volume":"124","author":"Zagon I.S.","year":"2006","unstructured":"Zagon I.S.; Sassani J.W.; Malefyt K.J.; McLaughlin P.J.; Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol 2006,124(11),1620-1624","journal-title":"Arch Ophthalmol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s004170000144","volume":"238","author":"K&#xF6;nig Merediz S.A.","year":"2000","unstructured":"K&#xF6;nig Merediz S.A.; Zhang E.P.; Wittig B.; Hoffmann F.; Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol 2000,238(8),701-707","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00417-002-0536-1","volume":"240","author":"M&#xFC;ller A.","year":"2002","unstructured":"M&#xFC;ller A.; Zhang E.P.; Schroff M.; Wittig B.; Hoffmann F.; Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. Graefes Arch Clin Exp Ophthalmol 2002,240(10),851-859","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.preteyeres.2005.04.001","volume":"24","author":"Mohan R.R.","year":"2005","unstructured":"Mohan R.R.; Sharma A.; Netto M.V.; Sinha S.; Wilson S.E.; Gene therapy in the cornea. Prog Retin Eye Res 2005,24(5),537-559","journal-title":"Prog Retin Eye Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.preteyeres.2011.09.001","volume":"31","author":"Mohan R.R.","year":"2012","unstructured":"Mohan R.R.; Tovey J.C.; Sharma A.; Tandon A.; Gene therapy in the cornea: 2005--present. Prog Retin Eye Res 2012,31(1),43-64","journal-title":"Prog Retin Eye Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/gt.2009.41","volume":"16","author":"Bemelmans A.P.","year":"2009","unstructured":"Bemelmans A.P.; Arsenijevic Y.; Majo F.; Efficient lentiviral gene transfer into corneal stroma cells using a femtosecond laser. Gene Ther 2009,16(7),933-938","journal-title":"Gene Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/bjophthalmol-2015-307610","volume":"100","author":"Jumelle C.","year":"2016","unstructured":"Jumelle C.; Mauclair C.; Houzet J.; Bernard A.; He Z.; Forest F.; Perrache C.; Gain P.; Thuret G.; Delivery of macromolecules into the endothelium of whole ex vivo human cornea by femtosecond laser-activated carbon nanoparticles. Br J Ophthalmol 2016,100(8),1151-1156","journal-title":"Br J Ophthalmol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jgm.1011","volume":"9","author":"Toropainen E.","year":"2007","unstructured":"Toropainen E.; Hornof M.; Kaarniranta K.; Johansson P.; Urtti A.; Corneal epithelium as a platform for secretion of transgene products after transfection with liposomal gene eyedrops. J Gene Med 2007,9(3),208-216","journal-title":"J Gene Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.exer.2004.08.024","volume":"80","author":"Dannowski H.","year":"2005","unstructured":"Dannowski H.; Bednarz J.; Reszka R.; Engelmann K.; Pleyer U.; Lipid-mediated gene transfer of acidic fibroblast growth factor into human corneal endothelial cells. Exp Eye Res 2005,80(1),93-101","journal-title":"Exp Eye Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature14580","volume":"524","author":"Rossi A.","year":"2015","unstructured":"Rossi A.; Kontarakis Z.; Gerri C.; Nolte H.; H&#xF6;lper S.; Kr&#xFC;ger M.; Stainier D.Y.; Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 2015,524(7564),230-233","journal-title":"Nature"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","volume":"5","author":"Scoles D.R.","year":"2019","unstructured":"Scoles D.R.; Minikel E.V.; Pulst S.M.; Antisense oligonucleotides: A primer. Neurol Genet 2019,5(2),e323","journal-title":"Neurol Genet"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","volume":"121","author":"Cursiefen C.","year":"2014","unstructured":"Cursiefen C.; Viaud E.; Bock F.; Geudelin B.; Ferry A.; Kadlecov&#xE1; P.; L&#xE9;vy M.; Al Mahmood S.; Colin S.; Thorin E.; Majo F.; Frueh B.; Wilhelm F.; Meyer-Ter-Vehn T.; Geerling G.; B&#xF6;hringer D.; Reinhard T.; Meller D.; Pleyer U.; Bachmann B.; Seitz B.; Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study. Ophthalmology 2014,121(9),1683-1692","journal-title":"Ophthalmology"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","volume":"116","author":"Cursiefen C.","year":"2009","unstructured":"Cursiefen C.; Bock F.; Horn F.K.; Kruse F.E.; Seitz B.; Borderie V.; Fr&#xFC;h B.; Thiel M.A.; Wilhelm F.; Geudelin B.; Descohand I.; Steuhl K.P.; Hahn A.; Meller D.; GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: Interim results of a randomized phase II trial. Ophthalmology 2009,116(9),1630-1637","journal-title":"Ophthalmology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1167\/iovs.03-0312","volume":"44","author":"Wasmuth S.","year":"2003","unstructured":"Wasmuth S.; Bauer D.; Yang Y.; Steuhl K.P.; Heiligenhaus A.; Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-alpha in herpetic stromal keratitis. Invest Ophthalmol Vis Sci 2003,44(12),5228-5234","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"594869","DOI":"10.1155\/2012\/594869","volume":"2012","author":"Elbadawy H.M.","year":"2012","unstructured":"Elbadawy H.M.; Gailledrat M.; Desseaux C.; Ponzin D.; Ferrari S.; Targeting herpetic keratitis by gene therapy. J Ophthalmol 2012,2012,594869","journal-title":"J Ophthalmol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/hmg\/ddy018","volume":"27","author":"Hu J.","year":"2018","unstructured":"Hu J.; Rong Z.; Gong X.; Zhou Z.; Sharma V.K.; Xing C.; Watts J.K.; Corey D.R.; Mootha V.V.; Oligonucleotides targeting TCf4 triplet repeat expansion inhibit RNA foci and mis-splicing in Fuchs\u2019 dystrophy. Hum Mol Genet 2018,27(6),1015-1026","journal-title":"Hum Mol Genet"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"102332","DOI":"10.1016\/j.nano.2020.102332","volume":"32","author":"Kramerov A.A.","year":"2020","unstructured":"Kramerov A.A.; Shah R.; Ding H.; Holler E.; Turjman S.; Rabinowitz Y.S.; Ghiam S.; Maguen E.; Svendsen C.N.; Saghizadeh M.; Ljubimova J.Y.; Ljubimov A.V.; Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells. Nanomedicine (Lond) 2020,32,102332","journal-title":"Nanomedicine (Lond)"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ajhg.2018.02.010","volume":"102","author":"Zarouchlioti C.","year":"2018","unstructured":"Zarouchlioti C.; Sanchez-Pintado B.; Hafford Tear N.J.; Klein P.; Liskova P.; Dulla K.; Semo M.; Vugler A.A.; Muthusamy K.; Dudakova L.; Levis H.J.; Skalicka P.; Hysi P.; Cheetham M.E.; Tuft S.J.; Adamson P.; Hardcastle A.J.; Davidson A.E.; Antisense therapy for a common corneal dystrophy ameliorates TCf4 repeat expansion-mediated toxicity. Am J Hum Genet 2018,102(4),528-539","journal-title":"Am J Hum Genet"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1089\/nat.2016.0654","volume":"27","author":"Gibson D.J.","year":"2017","unstructured":"Gibson D.J.; Tuli S.S.; Schultz G.S.; Dual-phase iontophoresis for the delivery of antisense oligonucleotides. Nucleic Acid Ther 2017,27(4),238-250","journal-title":"Nucleic Acid Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/nat.2019.0838","volume":"30","author":"Chau V.Q.","year":"2020","unstructured":"Chau V.Q.; Hu J.; Gong X.; Hulleman J.D.; Ufret-Vincenty R.L.; Rigo F.; Prakash T.P.; Corey D.R.; Mootha V.V.; Delivery of antisense oligonucleotides to the cornea. Nucleic Acid Ther 2020,30(4),207-214","journal-title":"Nucleic Acid Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.exer.2020.108329","volume":"202","author":"Supe S.","year":"2021","unstructured":"Supe S.; Upadhya A.; Singh K.; Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review. Exp Eye Res 2021,202,108329","journal-title":"Exp Eye Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2174\/156652412802480907","volume":"12","author":"Liu Q.","year":"2012","unstructured":"Liu Q.; Wu K.; Qiu X.; Yang Y.; Lin X.; Yu M.; siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice. Curr Mol Med 2012,12(8),1015-1027","journal-title":"Curr Mol Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1167\/iovs.13-12957","volume":"55","author":"Courtney D.G.","year":"2014","unstructured":"Courtney D.G.; Atkinson S.D.; Allen E.H.; Moore J.E.; Walsh C.P.; Pedrioli D.M.; MacEwen C.J.; Pellegrini G.; Maurizi E.; Serafini C.; Fantacci M.; Liao H.; Irvine A.D.; McLean W.H.; Moore C.B.; siRNA silencing of the mutant keratin 12 allele in corneal limbal epithelial cells grown from patients with Meesmann\u2019s epithelial corneal dystrophy. Invest Ophthalmol Vis Sci 2014,55(5),3352-3360","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00417-015-3067-2","volume":"253","author":"Qin Q.","year":"2015","unstructured":"Qin Q.; Shi Y.; Zhao Q.; Luo D.; Chen Y.; Wu J.; Zhao M.; Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection. Graefes Arch Clin Exp Ophthalmol 2015,253(10),1765-1776","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bph.12330","volume":"170","author":"Guzman-Aranguez A.","year":"2013","unstructured":"Guzman-Aranguez A.; Loma P.; Pintor J.; Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol 2013,170(4),730-747","journal-title":"Br J Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1167\/iovs.13-13233","volume":"54","author":"Saghizadeh M.","year":"2013","unstructured":"Saghizadeh M.; Epifantseva I.; Hemmati D.M.; Ghiam C.A.; Brunken W.J.; Ljubimov A.V.; Enhanced wound healing, kinase and stem cell marker expression in diabetic organ-cultured human corneas upon MMP-10 and cathepsin F gene silencing. Invest Ophthalmol Vis Sci 2013,54(13),8172-8180","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.exer.2014.10.022","volume":"129","author":"Saghizadeh M.","year":"2014","unstructured":"Saghizadeh M.; Dib C.M.; Brunken W.J.; Ljubimov A.V.; Normalization of wound healing and stem cell marker patterns in organ-cultured human diabetic corneas by gene therapy of limbal cells. Exp Eye Res 2014,129,66-73","journal-title":"Exp Eye Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.omtn.2019.07.017","volume":"17","author":"Schiroli D.","year":"2019","unstructured":"Schiroli D.; G&#xF3;mara M.J.; Maurizi E.; Atkinson S.D.; Mairs L.; Christie K.A.; Cobice D.F.; McCrudden C.M.; Nesbit M.A.; Haro I.; Moore T.; Effective in vivo topical delivery of siRNA and gene silencing in intact corneal epithelium using a modified cell-penetrating peptide. Mol Ther Nucleic Acids 2019,17,891-906","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","volume":"326","author":"Baran-Rachwalska P.","year":"2020","unstructured":"Baran-Rachwalska P.; Torabi-Pour N.; Sutera F.M.; Ahmed M.; Thomas K.; Nesbit M.A.; Welsh M.; Moore C.B.T.; Saffie-Siebert S.R.; Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles. J Control Release 2020,326,192-202","journal-title":"J Control Release"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.addr.2020.06.011","volume":"168","author":"Yu W.","year":"2021","unstructured":"Yu W.; Wu Z.; Ocular delivery of CRISPR\/Cas genome editing components for treatment of eye diseases. Adv Drug Deliv Rev 2021,168,181-195","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Wu Z.","year":"2010","unstructured":"Wu Z.; Yang H.; Colosi P.; Effect of genome size on AAV vector packaging. Mol Ther 2010,18(1),80-86","journal-title":"Mol Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.virusres.2011.03.026","volume":"158","author":"Suzuki T.","year":"2011","unstructured":"Suzuki T.; Sasaki T.; Yano K.; Sakurai F.; Kawabata K.; Kondoh M.; Hayakawa T.; Yagi K.; Mizuguchi H.; Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome. Virus Res 2011,158(1-2),154-160","journal-title":"Virus Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/gt.2011.153","volume":"19","author":"Balaggan K.S.","year":"2012","unstructured":"Balaggan K.S.; Ali R.R.; Ocular gene delivery using lentiviral vectors. Gene Ther 2012,19(2),145-153","journal-title":"Gene Ther"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nbt.3469","volume":"34","author":"Yang Y.","year":"2016","unstructured":"Yang Y.; Wang L.; Bell P.; McMenamin D.; He Z.; White J.; Yu H.; Xu C.; Morizono H.; Musunuru K.; Batshaw M.L.; Wilson J.M.; A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 2016,34(3),334-338","journal-title":"Nat Biotechnol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/pnas.1706193114","volume":"114","author":"Jain A.","year":"2017","unstructured":"Jain A.; Zode G.; Kasetti R.B.; Ran F.A.; Yan W.; Sharma T.P.; Bugge K.; Searby C.C.; Fingert J.H.; Zhang F.; Clark A.F.; Sheffield V.C.; CRISPR-Cas9-based treatment of myocilin-associated glaucoma. Proc Natl Acad Sci USA 2017,114(42),11199-11204","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","volume":"9","author":"Holmgaard A.","year":"2017","unstructured":"Holmgaard A.; Askou A.L.; Benckendorff J.N.E.; Thomsen E.A.; Cai Y.; Bek T.; Mikkelsen J.G.; Corydon T.J.; In vivo knockout of the VEGFA gene by lentiviral delivery of CRISPR\/Cas9 in mouse retinal pigment epithelium cells. Mol Ther Nucleic Acids 2017,9,89-99","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/mt.2009.256","volume":"18","author":"Lai Y.","year":"2010","unstructured":"Lai Y.; Yue Y.; Duan D.; Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010,18(1),75-79","journal-title":"Mol Ther"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.devcel.2014.07.018","volume":"30","author":"Wang S.","year":"2014","unstructured":"Wang S.; Sengel C.; Emerson M.M.; Cepko C.L.; A gene regulatory network controls the binary fate decision of rod and bipolar cells in the vertebrate retina. Dev Cell 2014,30(5),513-527","journal-title":"Dev Cell"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/mt.2015.220","volume":"24","author":"Bakondi B.","year":"2016","unstructured":"Bakondi B.; Lv W.; Lu B.; Jones M.K.; Tsai Y.; Kim K.J.; Levy R.; Akhtar A.A.; Breunig J.J.; Svendsen C.N.; Wang S.; In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol Ther 2016,24(3),556-563","journal-title":"Mol Ther"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","volume":"14","author":"Chen G.","year":"2019","unstructured":"Chen G.; Abdeen A.A.; Wang Y.; Shahi P.K.; Robertson S.; Xie R.; Suzuki M.; Pattnaik B.R.; Saha K.; Gong S.; A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol 2019,14(10),974-980","journal-title":"Nat Nanotechnol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2020.04.052","volume":"324","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Shahi P.K.; Xie R.; Zhang H.; Abdeen A.A.; Yodsanit N.; Ma Z.; Saha K.; Pattnaik B.R.; Gong S.; A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. J Control Release 2020,324,194-203","journal-title":"J Control Release"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","volume":"12","author":"Gaudana R.","year":"2010","unstructured":"Gaudana R.; Ananthula H.K.; Parenky A.; Mitra A.K.; Ocular drug delivery. AAPS J 2010,12(3),348-360","journal-title":"AAPS J"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/jop.2015.0047","volume":"32","author":"Yellepeddi V.K.","year":"2016","unstructured":"Yellepeddi V.K.; Palakurthi S.; Recent Advances in Topical Ocular Drug Delivery. J Ocul Pharmacol Ther 2016,32(2),67-82","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/nnm-2016-0379","volume":"12","author":"Joseph R.R.","year":"2017","unstructured":"Joseph R.R.; Venkatraman S.S.; Drug delivery to the eye: What benefits do nanocarriers offer? Nanomedicine (Lond) 2017,12(6),683-702","journal-title":"Nanomedicine (Lond)"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","volume":"370","author":"Gote V.","year":"2019","unstructured":"Gote V.; Sikder S.; Sicotte J.; Pal D.; Ocular drug delivery: Present innovations and future challenges. J Pharmacol Exp Ther 2019,370(3),602-624","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s10792-020-01391-8","volume":"40","author":"Rafiei F.","year":"2020","unstructured":"Rafiei F.; Tabesh H.; Farzad F.; Sustained subconjunctival drug delivery systems: Current trends and future perspectives. Int Ophthalmol 2020,40(9),2385-2401","journal-title":"Int Ophthalmol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/17425247.5.5.567","volume":"5","author":"Barar J.","year":"2008","unstructured":"Barar J.; Javadzadeh A.R.; Omidi Y.; Ocular novel drug delivery: Impacts of membranes and barriers. Expert Opin Drug Deliv 2008,5(5),567-581","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.1016\/S2214-109X(17)30293-0","volume":"5","author":"Bourne R.R.A.","year":"2017","unstructured":"Bourne R.R.A.; Flaxman S.R.; Braithwaite T.; Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: A systematic review and meta-analysis. Lancet Glob Health 2017,5(9),e888-e897","journal-title":"Lancet Glob Health"},{"key":"ref=132","year":"2019","unstructured":"World Health Organization Report. Visual impairment and blindness fact sheet. Available from: 2019"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2017.08.001","volume":"60","author":"Shu D.Y.","year":"2017","unstructured":"Shu D.Y.; Lovicu F.J.; Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis. Prog Retin Eye Res 2017,60,44-65","journal-title":"Prog Retin Eye Res"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.exer.2015.07.009","volume":"142","author":"Myofibroblasts H.B.","year":"2016","unstructured":"Myofibroblasts H.B.; Exp Eye Res 2016,142,56-70","journal-title":"Exp Eye Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.exer.2010.05.013","volume":"91","author":"Mohan R.R.","year":"2010","unstructured":"Mohan R.R.; Gupta R.; Mehan M.K.; Cowden J.W.; Sinha S.; Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Res 2010,91(2),238-245","journal-title":"Exp Eye Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"21305","DOI":"10.1074\/jbc.R800020200","volume":"283","author":"Schaefer L.","year":"2008","unstructured":"Schaefer L.; Iozzo R.V.; Biological functions of the small leucine-rich proteoglycans: From genetics to signal transduction. J Biol Chem 2008,283(31),21305-21309","journal-title":"J Biol Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/346281a0","volume":"346","author":"Yamaguchi Y.","year":"1990","unstructured":"Yamaguchi Y.; Mann D.M.; Ruoslahti E.; Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990,346(6281),281-284","journal-title":"Nature"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0076-6879(94)45014-5","volume":"245","author":"Harper J.R.","year":"1994","unstructured":"Harper J.R.; Spiro R.C.; Gaarde W.A.; Tamura R.N.; Pierschbacher M.D.; Noble N.A.; Stecker K.K.; Border W.A.; Role of transforming growth factor beta and decorin in controlling fibrosis. Methods Enzymol 1994,245,241-254","journal-title":"Methods Enzymol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yexmp.2004.07.006","volume":"78","author":"Huijun W.","year":"2005","unstructured":"Huijun W.; Long C.; Zhigang Z.; Feng J.; Muyi G.; Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 2005,78(1),17-24","journal-title":"Exp Mol Pathol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/vop.12060","volume":"17","author":"Donnelly K.S.","year":"2014","unstructured":"Donnelly K.S.; Giuliano E.A.; Sharma A.; Tandon A.; Rodier J.T.; Mohan R.R.; Decorin-PEI nanoconstruct attenuates equine corneal fibroblast differentiation. Vet Ophthalmol 2014,17(3),162-169","journal-title":"Vet Ophthalmol"},{"key":"ref=141","first-page":"2598","volume":"18","author":"Sharma A.","year":"2012","unstructured":"Sharma A.; Rodier J.T.; Tandon A.; Klibanov A.M.; Mohan R.R.; Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-&#x3B2; type II receptor (sTGF&#x3B2;RII) gene transfer. Mol Vis 2012,18,2598-2607","journal-title":"Mol Vis"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"f1006","DOI":"10.1152\/ajprenal.00382.2002","volume":"284","author":"Wang S.","year":"2003","unstructured":"Wang S.; Hirschberg R.; BMP7 antagonizes TGF-&#x3B2; -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003,284(5),f1006-f1013","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"23200","DOI":"10.1074\/jbc.M311998200","volume":"279","author":"Wang S.","year":"2004","unstructured":"Wang S.; Hirschberg R.; Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004,279(22),23200-23206","journal-title":"J Biol Chem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/39369","volume":"389","author":"Nakao A.","year":"1997","unstructured":"Nakao A.; Afrakhte M.; Mor&#xE9;n A.; Nakayama T.; Christian J.L.; Heuchel R.; Itoh S.; Kawabata M.; Heldin N.E.; Heldin C.H.; ten Dijke P.; Identification of Smad7, a TGFbeta-inducible antagonist of TGF-&#x3B2; signalling. Nature 1997,389(6651),631-635","journal-title":"Nature"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/labinvest.3700247","volume":"85","author":"Saika S.","year":"2005","unstructured":"Saika S.; Ikeda K.; Yamanaka O.; Flanders K.C.; Nakajima Y.; Miyamoto T.; Ohnishi Y.; Kao W.W.; Muragaki Y.; Ooshima A.; Therapeutic effects of adenoviral gene transfer of bone morphogenic protein-7 on a corneal alkali injury model in mice. Lab Invest 2005,85(4),474-486","journal-title":"Lab Invest"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1167\/iovs.17-23308","volume":"59","author":"Gupta S.","year":"2018","unstructured":"Gupta S.; Fink M.K.; Ghosh A.; Tripathi R.; Sinha P.R.; Sharma A.; Hesemann N.P.; Chaurasia S.S.; Giuliano E.A.; Mohan R.R.; Novel combination BMP7 and HGF gene therapy instigates selective myofibroblast apoptosis and reduces corneal haze in vivo. Invest Ophthalmol Vis Sci 2018,59(2),1045-1057","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=147","first-page":"1975","volume":"40","author":"Cordeiro M.F.","year":"1999","unstructured":"Cordeiro M.F.; Reichel M.B.; Gay J.A.; D\u2019Esposita F.; Alexander R.A.; Khaw P.T.; Transforming growth factor-&#x3B2;1, -&#x3B2;2, and -&#x3B2;3 in vivo: Effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999,40(9),1975-1982","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/sj.gt.3301865","volume":"10","author":"Cordeiro M.F.","year":"2003","unstructured":"Cordeiro M.F.; Mead A.; Ali R.R.; Alexander R.A.; Murray S.; Chen C.; York-Defalco C.; Dean N.M.; Schultz G.S.; Khaw P.T.; Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 2003,10(1),59-71","journal-title":"Gene Ther"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41598-020-80542-4","volume":"11","author":"Chun Y.Y.","year":"2021","unstructured":"Chun Y.Y.; Yap Z.L.; Seet L.F.; Chan H.H.; Toh L.Z.; Chu S.W.L.; Lee Y.S.; Wong T.T.; Tan T.T.Y.; Positive-charge tuned gelatin hydrogel-siSPARC injectable for siRNA anti-scarring therapy in post glaucoma filtration surgery. Sci Rep 2021,11(1),1470","journal-title":"Sci Rep"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"C75","DOI":"10.1152\/ajpcell.00332.2006","volume":"293","author":"Saika S.","year":"2007","unstructured":"Saika S.; Yamanaka O.; Okada Y.; Miyamoto T.; Kitano A.; Flanders K.C.; Ohnishi Y.; Nakajima Y.; Kao W.W.; Ikeda K.; Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice. Am J Physiol Cell Physiol 2007,293(1),C75-C86","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=151","first-page":"968","volume":"43","author":"Behrens A.","year":"2002","unstructured":"Behrens A.; Gordon E.M.; Li L.; Liu P.X.; Chen Z.; Peng H.; La Bree L.; Anderson W.F.; Hall F.L.; McDonnell P.J.; Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci 2002,43(4),968-977","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","volume":"49","author":"Ljubimov A.V.","year":"2015","unstructured":"Ljubimov A.V.; Saghizadeh M.; Progress in corneal wound healing. Prog Retin Eye Res 2015,49,17-45","journal-title":"Prog Retin Eye Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0002-9440(10)64015-1","volume":"158","author":"Saghizadeh M.","year":"2001","unstructured":"Saghizadeh M.; Brown D.J.; Castellon R.; Chwa M.; Huang G.H.; Ljubimova J.Y.; Rosenberg S.; Spirin K.S.; Stolitenko R.B.; Adachi W.; Kinoshita S.; Murphy G.; Windsor L.J.; Kenney M.C.; Ljubimov A.V.; Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: A possible mechanism of basement membrane and integrin alterations. Am J Pathol 2001,158(2),723-734","journal-title":"Am J Pathol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1167\/iovs.04-1507","volume":"46","author":"Saghizadeh M.","year":"2005","unstructured":"Saghizadeh M.; Kramerov A.A.; Tajbakhsh J.; Aoki A.M.; Wang C.; Chai N.N.; Ljubimova J.Y.; Sasaki T.; Sosne G.; Carlson M.R.; Nelson S.F.; Ljubimov A.V.; Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci 2005,46(10),3604-3615","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1167\/iovs.02-0442","volume":"44","author":"Daniels J.T.","year":"2003","unstructured":"Daniels J.T.; Limb G.A.; Saarialho-Kere U.; Murphy G.; Khaw P.T.; Human corneal epithelial cells require MMP-1 for HGF-mediated migration on collagen I. Invest Ophthalmol Vis Sci 2003,44(3),1048-1055","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/path.1578","volume":"203","author":"Bevan D.","year":"2004","unstructured":"Bevan D.; Gherardi E.; Fan T.P.; Edwards D.; Warn R.; Diverse and potent activities of HGF\/SF in skin wound repair. J Pathol 2004,203(3),831-838","journal-title":"J Pathol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1167\/iovs.04-0372","volume":"45","author":"Kakazu A.","year":"2004","unstructured":"Kakazu A.; Chandrasekher G.; Bazan H.E.; HGF protects corneal epithelial cells from apoptosis by the PI-3K\/Akt-1\/Bad- but not the ERK1\/2-mediated signaling pathway. Invest Ophthalmol Vis Sci 2004,45(10),3485-3492","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1634\/stemcells.22-3-405","volume":"22","author":"Neuss S.","year":"2004","unstructured":"Neuss S.; Becher E.; W&#xF6;ltje M.; Tietze L.; Jahnen-Dechent W.; Functional expression of HGF and HGF receptor\/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004,22(3),405-414","journal-title":"Stem Cells"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1083\/jcb.200701086","volume":"177","author":"Chmielowiec J.","year":"2007","unstructured":"Chmielowiec J.; Borowiak M.; Morkel M.; Stradal T.; Munz B.; Werner S.; Wehland J.; Birchmeier C.; Birchmeier W.; c-Met is essential for wound healing in the skin. J Cell Biol 2007,177(1),151-162","journal-title":"J Cell Biol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.brainresbull.2009.10.007","volume":"81","author":"Saghizadeh M.","year":"2010","unstructured":"Saghizadeh M.; Kramerov A.A.; Yaghoobzadeh Y.; Hu J.; Ljubimova J.Y.; Black K.L.; Castro M.G.; Ljubimov A.V.; Adenovirus-driven overexpression of proteinases in organ-cultured normal human corneas leads to diabetic-like changes. Brain Res Bull 2010,81(2-3),262-272","journal-title":"Brain Res Bull"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"e54058","DOI":"10.3791\/54058","volume":"110","author":"Kramerov A.A.","year":"2016","unstructured":"Kramerov A.A.; Saghizadeh M.; Ljubimov A.V.; Adenoviral gene therapy for diabetic keratopathy: Effects on wound healing and stem cell marker expression in human organ-cultured corneas and limbal epithelial cells. J Vis Exp 2016,110(110),e54058","journal-title":"J Vis Exp"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"9703729","DOI":"10.1155\/2016\/9703729","volume":"2016","author":"Sassani J.W.","year":"2016","unstructured":"Sassani J.W.; Mc Laughlin P.J.; Zagon I.S.; The Yin and Yang of the opioid growth regulatory system: Focus on diabetes-The Lorenz E. Zimmerman Tribute Lecture. J Diabetes Res 2016,2016,9703729","journal-title":"J Diabetes Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"e84425","DOI":"10.1371\/journal.pone.0084425","volume":"8","author":"Funari V.A.","year":"2013","unstructured":"Funari V.A.; Winkler M.; Brown J.; Dimitrijevich S.D.; Ljubimov A.V.; Saghizadeh M.; Differentially expressed wound healing-related microRNAs in the human diabetic cornea. PLoS One 2013,8(12),e84425","journal-title":"PLoS One"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"e114692","DOI":"10.1371\/journal.pone.0114692","volume":"9","author":"Winkler M.A.","year":"2014","unstructured":"Winkler M.A.; Dib C.; Ljubimov A.V.; Saghizadeh M.; Targeting miR-146a to treat delayed wound healing in human diabetic organ-cultured corneas. PLoS One 2014,9(12),e114692","journal-title":"PLoS One"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/02713683.2019.1707229","volume":"45","author":"Wang F.","year":"2020","unstructured":"Wang F.; Wang D.; Song M.; Zhou Q.; Liao R.; Wang Y.; MiRNA-155-5p reduces corneal epithelial permeability by remodeling epithelial tight junctions during corneal wound healing. Curr Eye Res 2020,45(8),904-913","journal-title":"Curr Eye Res"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/09273948.2010.486100","volume":"18","author":"Niederkorn J.Y.","year":"2010","unstructured":"Niederkorn J.Y.; Larkin D.F.; Immune privilege of corneal allografts. Ocul Immunol Inflamm 2010,18(3),162-171","journal-title":"Ocul Immunol Inflamm"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1755-3768.2009.01596.x","volume":"87","author":"Pleyer U.","year":"2009","unstructured":"Pleyer U.; Schlickeiser S.; The taming of the shrew? The immunology of corneal transplantation. Acta Ophthalmol 2009,87(5),488-497","journal-title":"Acta Ophthalmol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000350547","volume":"50","author":"Ritter T.","year":"2013","unstructured":"Ritter T.; Wilk M.; Nosov M.; Gene therapy approaches to prevent corneal graft rejection: Where do we stand? Ophthalmic Res 2013,50(3),135-140","journal-title":"Ophthalmic Res"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1517\/14712598.4.7.1059","volume":"4","author":"Williams K.A.","year":"2004","unstructured":"Williams K.A.; Jessup C.F.; Coster D.J.; Gene therapy approaches to prolonging corneal allograft survival. Expert Opin Biol Ther 2004,4(7),1059-1071","journal-title":"Expert Opin Biol Ther"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.gt.3300443","volume":"4","author":"Oral H.B.","year":"1997","unstructured":"Oral H.B.; Larkin D.F.; Fehervari Z.; Byrnes A.P.; Rankin A.M.; Haskard D.O.; Wood M.J.; Dallman M.J.; George A.J.; Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Ther 1997,4(7),639-647","journal-title":"Gene Ther"},{"key":"ref=171","first-page":"1095","volume":"43","author":"Comer R.M.","year":"2002","unstructured":"Comer R.M.; King W.J.; Ardjomand N.; Theoharis S.; George A.J.; Larkin D.F.; Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci 2002,43(4),1095-1103","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=172","first-page":"1389","volume":"16","author":"Zhou S.Y.","year":"2010","unstructured":"Zhou S.Y.; Xie Z.L.; Xiao O.; Yang X.R.; Heng B.C.; Sato Y.; Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis 2010,16,1389-1398","journal-title":"Mol Vis"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/00007890-200105150-00006","volume":"71","author":"Klebe S.","year":"2001","unstructured":"Klebe S.; Sykes P.J.; Coster D.J.; Krishnan R.; Williams K.A.; Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001,71(9),1214-1220","journal-title":"Transplantation"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.gt.3302884","volume":"14","author":"Gong N.","year":"2007","unstructured":"Gong N.; Pleyer U.; Volk H.D.; Ritter T.; Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther 2007,14(6),484-490","journal-title":"Gene Ther"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1442-9071.2010.02261.x","volume":"38","author":"Parker D.G.","year":"2010","unstructured":"Parker D.G.; Coster D.J.; Brereton H.M.; Hart P.H.; Koldej R.; Anson D.S.; Williams K.A.; Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Exp Ophthalmol 2010,38(4),405-413","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.4049\/jimmunol.175.4.2219","volume":"175","author":"Klebe S.","year":"2005","unstructured":"Klebe S.; Coster D.J.; Sykes P.J.; Swinburne S.; Hallsworth P.; Scheerlinck J.P.; Krishnan R.; Williams K.A.; Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol 2005,175(4),2219-2226","journal-title":"J Immunol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.trim.2007.05.004","volume":"18","author":"Ritter T.","year":"2007","unstructured":"Ritter T.; Yang J.; Dannowski H.; Vogt K.; Volk H.D.; Pleyer U.; Effects of interleukin-12p40 gene transfer on rat corneal allograft survival. Transpl Immunol 2007,18(2),101-107","journal-title":"Transpl Immunol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"e60714","DOI":"10.1371\/journal.pone.0060714","volume":"8","author":"Yuan J.","year":"2013","unstructured":"Yuan J.; Liu Y.; Huang W.; Zhou S.; Ling S.; Chen J.; The experimental treatment of corneal graft rejection with the interleukin-1 receptor antagonist (IL-1ra) gene. PLoS One 2013,8(5),e60714","journal-title":"PLoS One"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1600-6143.2011.03948.x","volume":"12","author":"Nosov M.","year":"2012","unstructured":"Nosov M.; Wilk M.; Morcos M.; Cregg M.; O\u2019Flynn L.; Treacy O.; Ritter T.; Role of lentivirus-mediated overexpression of programmed death-ligand 1 on corneal allograft survival. Am J Transplant 2012,12(5),1313-1322","journal-title":"Am J Transplant"},{"key":"ref=180","first-page":"2887","volume":"41","author":"Albon J.","year":"2000","unstructured":"Albon J.; Tullo A.B.; Aktar S.; Boulton M.E.; Apoptosis in the endothelium of human corneas for transplantation. Invest Ophthalmol Vis Sci 2000,41(10),2887-2893","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/hum.2017.044","volume":"29","author":"Pastak M.","year":"2018","unstructured":"Pastak M.; Kleff V.; Saban D.R.; Czugala M.; Steuhl K.P.; Erg&#xFC;n S.; Singer B.B.; Fuchsluger T.A.; Gene therapy for modulation of T-cell-mediated immune response provoked by corneal transplantation. Hum Gene Ther 2018,29(4),467-479","journal-title":"Hum Gene Ther"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/j.1600-6143.2007.01897.x","volume":"7","author":"Barcia R.N.","year":"2007","unstructured":"Barcia R.N.; Dana M.R.; Kazlauskas A.; Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplant 2007,7(9),2082-2089","journal-title":"Am J Transplant"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/gt.2011.20","volume":"18","author":"Fuchsluger T.A.","year":"2011","unstructured":"Fuchsluger T.A.; Jurkunas U.; Kazlauskas A.; Dana R.; Anti-apoptotic gene therapy prolongs survival of corneal endothelial cells during storage. Gene Ther 2011,18(8),778-787","journal-title":"Gene Ther"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1089\/hum.2010.079","volume":"22","author":"Fuchsluger T.A.","year":"2011","unstructured":"Fuchsluger T.A.; Jurkunas U.; Kazlauskas A.; Dana R.; Corneal endothelial cells are protected from apoptosis by gene therapy. Hum Gene Ther 2011,22(5),549-558","journal-title":"Hum Gene Ther"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.exer.2018.07.006","volume":"176","author":"Torrecilla J.","year":"2018","unstructured":"Torrecilla J.; Del Pozo-Rodr&#xED;guez A.; Vicente-Pascual M.; Solin&#xED;s M.&#xC1;.; Rodr&#xED;guez-Gasc&#xF3;n A.; Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis. Exp Eye Res 2018,176,130-140","journal-title":"Exp Eye Res"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/sj.gt.3301695","volume":"9","author":"Lai Y.K.","year":"2002","unstructured":"Lai Y.K.; Shen W.Y.; Brankov M.; Lai C.M.; Constable I.J.; Rakoczy P.E.; Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002,9(12),804-813","journal-title":"Gene Ther"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/ICO.0b013e318206c893","volume":"30","author":"Iriyama A.","year":"2011","unstructured":"Iriyama A.; Usui T.; Yanagi Y.; Amano S.; Oba M.; Miyata K.; Nishiyama N.; Kataoka K.; Gene transfer using micellar nanovectors inhibits corneal neovascularization in vivo. Cornea 2011,30(12),1423-1427","journal-title":"Cornea"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bbrc.2007.07.114","volume":"361","author":"Yu H.","year":"2007","unstructured":"Yu H.; Wu J.; Li H.; Wang Z.; Chen X.; Tian Y.; Yi M.; Ji X.; Ma J.; Huang Q.; Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression. Biochem Biophys Res Commun 2007,361(4),946-952","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1006\/exer.2002.2075","volume":"75","author":"Lai C.M.","year":"2002","unstructured":"Lai C.M.; Spilsbury K.; Brankov M.; Zaknich T.; Rakoczy P.E.; Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 2002,75(6),625-634","journal-title":"Exp Eye Res"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1167\/iovs.11-9139","volume":"53","author":"Qazi Y.","year":"2012","unstructured":"Qazi Y.; Stagg B.; Singh N.; Singh S.; Zhang X.; Luo L.; Simonis J.; Kompella U.B.; Ambati B.K.; Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 2012,53(6),2837-2844","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/gt.2009.50","volume":"16","author":"Yoon K.C.","year":"2009","unstructured":"Yoon K.C.; Bae J.A.; Park H.J.; Im S.K.; Oh H.J.; Lin X.H.; Kim M.Y.; Lee J.H.; Lee S.E.; Ahn K.Y.; Kim K.K.; Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model. Gene Ther 2009,16(8),973-981","journal-title":"Gene Ther"},{"key":"ref=192","first-page":"2344","volume":"13","author":"Cheng H.C.","year":"2007","unstructured":"Cheng H.C.; Yeh S.I.; Tsao Y.P.; Kuo P.C.; Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis 2007,13,2344-2352","journal-title":"Mol Vis"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","volume":"14","author":"Lai L.J.","year":"2007","unstructured":"Lai L.J.; Xiao X.; Wu J.H.; Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci 2007,14(3),313-322","journal-title":"J Biomed Sci"},{"key":"ref=194","first-page":"310","volume":"16","author":"Chen P.","year":"2010","unstructured":"Chen P.; Yin H.; Wang Y.; Mi J.; He W.; Xie L.; Wang Y.; Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization. Mol Vis 2010,16,310-319","journal-title":"Mol Vis"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.exer.2009.06.021","volume":"89","author":"Kuo C.N.","year":"2009","unstructured":"Kuo C.N.; Yang L.C.; Yang C.T.; Lai C.H.; Chen M.F.; Chen C.Y.; Chen C.H.; Wu P.C.; Kou H.K.; Chen Y.J.; Hung C.H.; Tsai C.B.; Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. Exp Eye Res 2009,89(5),678-685","journal-title":"Exp Eye Res"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/nano9040631","volume":"9","author":"Torrecilla J.","year":"2019","unstructured":"Torrecilla J.; G&#xF3;mez-Aguado I.; Vicente-Pascual M.; Del Pozo-Rodr&#xED;guez A.; Solin&#xED;s M.&#xC1;.; Rodr&#xED;guez-Gasc&#xF3;n A.; MMP-9 downregulation with lipid nanoparticles for inhibiting corneal neovascularization by gene silencing. Nanomaterials (Basel) 2019,9(4),631","journal-title":"Nanomaterials (Basel)"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.exer.2019.03.006","volume":"184","author":"Chen J.","year":"2019","unstructured":"Chen J.; Li F.; Xu Y.; Zhang W.; Hu Y.; Fu Y.; Xu W.; Ge S.; Fan X.; Lu L.; Cholesterol modification of SDF-1-specific siRNA enables therapeutic targeting of angiogenesis through Akt pathway inhibition. Exp Eye Res 2019,184,64-71","journal-title":"Exp Eye Res"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.preteyeres.2018.01.004","volume":"65","author":"Moore C.B.T.","year":"2018","unstructured":"Moore C.B.T.; Christie K.A.; Marshall J.; Nesbit M.A.; Personalised genome editing - The future for corneal dystrophies. Prog Retin Eye Res 2018,65,147-165","journal-title":"Prog Retin Eye Res"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/gt.2015.82","volume":"23","author":"Courtney D.G.","year":"2016","unstructured":"Courtney D.G.; Moore J.E.; Atkinson S.D.; Maurizi E.; Allen E.H.; Pedrioli D.M.; McLean W.H.; Nesbit M.A.; Moore C.B.; CRISPR\/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. Gene Ther 2016,23(1),108-112","journal-title":"Gene Ther"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1167\/tvst.9.13.44","volume":"9","author":"Fu D.J.","year":"2020","unstructured":"Fu D.J.; Allen E.H.A.; Hickerson R.P.; Leslie Pedrioli D.M.; McLean W.H.I.; Development of a corneal bioluminescence mouse for real-time in vivo evaluation of gene therapies. Transl Vis Sci Technol 2020,9(13),44","journal-title":"Transl Vis Sci Technol"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1167\/iovs.13-13279","volume":"55","author":"Courtney D.G.","year":"2014","unstructured":"Courtney D.G.; Atkinson S.D.; Moore J.E.; Maurizi E.; Serafini C.; Pellegrini G.; Black G.C.; Manson F.D.; Yam G.H.; Macewen C.J.; Allen E.H.; McLean W.H.; Moore C.B.; Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type I. Invest Ophthalmol Vis Sci 2014,55(2),977-985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"16174","DOI":"10.1038\/s41598-017-16279-4","volume":"7","author":"Christie K.A.","year":"2017","unstructured":"Christie K.A.; Courtney D.G.; DeDionisio L.A.; Shern C.C.; De Majumdar S.; Mairs L.C.; Nesbit M.A.; Moore C.B.T.; Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders. Sci Rep 2017,7(1),16174","journal-title":"Sci Rep"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"16713","DOI":"10.1038\/s41598-017-16308-2","volume":"7","author":"Taketani Y.","year":"2017","unstructured":"Taketani Y.; Kitamoto K.; Sakisaka T.; Kimakura M.; Toyono T.; Yamagami S.; Amano S.; Kuroda M.; Moore T.; Usui T.; Ouchi Y.; Repair of the TGFBI gene in human corneal keratocytes derived from a granular corneal dystrophy patient via CRISPR\/Cas9-induced homology-directed repair. Sci Rep 2017,7(1),16713","journal-title":"Sci Rep"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"100843","DOI":"10.1016\/j.preteyeres.2020.100843","volume":"77","author":"Nielsen N.S.","year":"2020","unstructured":"Nielsen N.S.; Poulsen E.T.; Lukassen M.V.; Chao Shern C.; Mogensen E.H.; Weberskov C.E.; DeDionisio L.; Schauser L.; Moore T.C.B.; Otzen D.E.; Hjortdal J.; Enghild J.J.; Biochemical mechanisms of aggregation in TGFBI-linked corneal dystrophies. Prog Retin Eye Res 2020,77,100843","journal-title":"Prog Retin Eye Res"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ICL.0000000000000469","volume":"45","author":"Sarnicola C.","year":"2019","unstructured":"Sarnicola C.; Farooq A.V.; Colby K.; Fuchs endothelial corneal dystrophy: Update on pathogenesis and future directions. Eye Contact Lens 2019,45(1),1-10","journal-title":"Eye Contact Lens"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1167\/tvst.9.9.47","volume":"9","author":"Rong Z.","year":"2020","unstructured":"Rong Z.; Gong X.; Hulleman J.D.; Corey D.R.; Mootha V.V.; Trinucleotide repeat-targeting dcas9 as a therapeutic strategy for Fuchs\u2019 endothelial corneal dystrophy. Transl Vis Sci Technol 2020,9(9),47","journal-title":"Transl Vis Sci Technol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/archopht.1972.01000030414012","volume":"88","author":"Nesburn A.B.","year":"1972","unstructured":"Nesburn A.B.; Cook M.L.; Stevens J.G.; Latent herpes simplex virus. Isolation from rabbit trigeminal ganglia between episodes of recurrent ocular infection. Arch Ophthalmol 1972,88(4),412-417","journal-title":"Arch Ophthalmol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bjo.66.10.643","volume":"66","author":"Shimeld C.","year":"1982","unstructured":"Shimeld C.; Tullo A.B.; Easty D.L.; Thomsitt J.; Isolation of herpes simplex virus from the cornea in chronic stromal keratitis. Br J Ophthalmol 1982,66(10),643-647","journal-title":"Br J Ophthalmol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/QCO.0b013e328017f878","volume":"20","author":"Thomas P.A.","year":"2007","unstructured":"Thomas P.A.; Geraldine P.; Infectious keratitis. Curr Opin Infect Dis 2007,20(2),129-141","journal-title":"Curr Opin Infect Dis"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1128\/JVI.72.7.5545-5551.1998","volume":"72","author":"Chun S.","year":"1998","unstructured":"Chun S.; Daheshia M.; Kuklin N.A.; Rouse B.T.; Modulation of viral immunoinflammatory responses with cytokine DNA administered by different routes. J Virol 1998,72(7),5545-5551","journal-title":"J Virol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0264-410X(98)80105-9","volume":"16","author":"Daheshia M.","year":"1998","unstructured":"Daheshia M.; Kuklin N.; Manickan E.; Chun S.; Rouse B.T.; Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine 1998,16(11-12),1103-1110","journal-title":"Vaccine"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1189\/jlb.71.3.469","volume":"71","author":"Lee S.","year":"2002","unstructured":"Lee S.; Zheng M.; Deshpande S.; Eo S.K.; Hamilton T.A.; Rouse B.T.; IL-12 suppresses the expression of ocular immunoinflammatory lesions by effects on angiogenesis. J Leukoc Biol 2002,71(3),469-476","journal-title":"J Leukoc Biol"},{"key":"ref=213","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.4049\/jimmunol.162.7.4184","volume":"162","author":"Noisakran S.","year":"1999","unstructured":"Noisakran S.; Campbell I.L.; Carr D.J.; Ectopic expression of DNA encoding IFN-&#x3B1; 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J Immunol 1999,162(7),4184-4190","journal-title":"J Immunol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.4049\/jimmunol.164.12.6435","volume":"164","author":"Noisakran S.","year":"2000","unstructured":"Noisakran S.; Carr D.J.; Plasmid DNA encoding IFN-&#x3B1; 1 antagonizes herpes simplex virus type 1 ocular infection through CD4+ and CD8+ T lymphocytes. J Immunol 2000,164(12),6435-6443","journal-title":"J Immunol"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1076\/0271-3683(200005)2051-1FT405","volume":"20","author":"Noisakran S.J.","year":"2000","unstructured":"Noisakran S.J.; Carr D.J.; Therapeutic efficacy of DNA encoding IFN-&#x3B1;1 against corneal HSV-1 infection. Curr Eye Res 2000,20(5),405-412","journal-title":"Curr Eye Res"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0165-5728(01)00442-8","volume":"121","author":"Noisakran S.","year":"2001","unstructured":"Noisakran S.; Carr D.J.; Topical application of the cornea post-infection with plasmid DNA encoding interferon-&#x3B1;1 but not recombinant interferon-alphaA reduces herpes simplex virus type 1-induced mortality in mice. J Neuroimmunol 2001,121(1-2),49-58","journal-title":"J Neuroimmunol"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0165-5728(00)00264-2","volume":"108","author":"Cui B.","year":"2000","unstructured":"Cui B.; Carr D.J.; A plasmid construct encoding murine interferon beta antagonizes the replication of herpes simplex virus type I in vitro and in vivo. J Neuroimmunol 2000,108(1-2),92-102","journal-title":"J Neuroimmunol"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0264-410X(00)00242-5","volume":"19","author":"Caselli E.","year":"2000","unstructured":"Caselli E.; Balboni P.G.; Incorvaia C.; Argnani R.; Parmeggiani F.; Cassai E.; Manservigi R.; Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection. Vaccine 2000,19(9-10),1225-1231","journal-title":"Vaccine"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1167\/iovs.03-0828","volume":"45","author":"Osorio Y.","year":"2004","unstructured":"Osorio Y.; Cohen J.; Ghiasi H.; Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Invest Ophthalmol Vis Sci 2004,45(2),506-514","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00003226-200201000-00022","volume":"21","author":"Inoue T.","year":"2002","unstructured":"Inoue T.; Inoue Y.; Hayashi K.; Yoshida A.; Nishida K.; Shimomura Y.; Fujisawa Y.; Aono A.; Tano Y.; Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis. Cornea 2002,21(1),106-110","journal-title":"Cornea"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1097\/01.ico.0000263124.91639.4e","volume":"21","author":"Inoue T.","year":"2002","unstructured":"Inoue T.; Inoue Y.; Hayashi K.; Shimomura Y.; Fujisawa Y.; Aono A.; Tano Y.; Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis. Cornea 2002,21(7)(Suppl.),S79-S85","journal-title":"Cornea"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S0021-5155(02)00501-4","volume":"46","author":"Inoue T.","year":"2002","unstructured":"Inoue T.; Inoue Y.; Nakamura T.; Yoshida A.; Inoue Y.; Tano Y.; Shimomura Y.; Fujisawa Y.; Aono A.; Hayashi K.; The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis. Jpn J Ophthalmol 2002,46(4),370-376","journal-title":"Jpn J Ophthalmol"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"e00812","DOI":"10.1128\/JVI.00812-18","volume":"92","author":"Watson Z.L.","year":"2018","unstructured":"Watson Z.L.; Washington S.D.; Phelan D.M.; Lewin A.S.; Tuli S.S.; Schultz G.S.; Neumann D.M.; Bloom D.C.; In Vivo knockdown of the herpes simplex virus 1 latency-associated transcript reduces reactivation from latency. J Virol 2018,92(16),e00812-e00818","journal-title":"J Virol"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.antiviral.2009.07.020","volume":"84","author":"Moerdyk-Schauwecker M.","year":"2009","unstructured":"Moerdyk-Schauwecker M.; Stein D.A.; Eide K.; Blouch R.E.; Bildfell R.; Iversen P.; Jin L.; Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27. Antiviral Res 2009,84(2),131-141","journal-title":"Antiviral Res"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","volume":"165","author":"Kim B.","year":"2004","unstructured":"Kim B.; Tang Q.; Biswas P.S.; Xu J.; Schiffelers R.M.; Xie F.Y.; Ansari A.M.; Scaria P.V.; Woodle M.C.; Lu P.; Rouse B.T.; Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004,165(6),2177-2185","journal-title":"Am J Pathol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1073\/pnas.0831159100","volume":"100","author":"White R.R.","year":"2003","unstructured":"White R.R.; Shan S.; Rusconi C.P.; Shetty G.; Dewhirst M.W.; Kontos C.D.; Sullenger B.A.; Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003,100(9),5028-5033","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/mt.2010.302","volume":"19","author":"Grosse S.","year":"2011","unstructured":"Grosse S.; Huot N.; Mahiet C.; Arnould S.; Barradeau S.; Clerre D.L.; Chion-Sotinel I.; Jacqmarcq C.; Chapellier B.; Ergani A.; Desseaux C.; C&#xE9;drone F.; Conseiller E.; P&#xE2;ques F.; Labetoulle M.; Smith J.; Meganuclease-mediated Inhibition of HSV1 Infection in cultured cells. Mol Ther 2011,19(4),694-702","journal-title":"Mol Ther"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"119","DOI":"10.15283\/ijsc17029","volume":"10","author":"Daliri K.","year":"2017","unstructured":"Daliri K.; Ljubimov A.V.; Hekmatimoghaddam S.; Glaucoma, stem cells, and gene therapy: Where are we now? Int J Stem Cells 2017,10(2),119-128","journal-title":"Int J Stem Cells"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1167\/iovs.09-3847","volume":"51","author":"Buie L.K.","year":"2010","unstructured":"Buie L.K.; Rasmussen C.A.; Porterfield E.C.; Ramgolam V.S.; Choi V.W.; Markovic-Plese S.; Samulski R.J.; Kaufman P.L.; Borr&#xE1;s T.; Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci 2010,51(1),236-248","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"e0182473","DOI":"10.1371\/journal.pone.0182473","volume":"12","author":"Wang L.","year":"2017","unstructured":"Wang L.; Xiao R.; Andres-Mateos E.; Vandenberghe L.H.; Single stranded adeno-associated virus achieves efficient gene transfer to anterior segment in the mouse eye. PLoS One 2017,12(8),e0182473","journal-title":"PLoS One"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/hmg\/ddx028","volume":"26","author":"O\u2019Callaghan J.","year":"2017","unstructured":"O\u2019Callaghan J.; Crosbie D.E.; Cassidy P.S.; Sherwood J.M.; Fl&#xFC;gel-Koch C.; L&#xFC;tjen-Drecoll E.; Humphries M.M.; Reina-Torres E.; Wallace D.; Kiang A.S.; Campbell M.; Stamer W.D.; Overby D.R.; O\u2019Brien C.; Tam L.C.S.; Humphries P.; Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Hum Mol Genet 2017,26(7),1230-1246","journal-title":"Hum Mol Genet"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/aps.2009.23","volume":"30","author":"Yang J.G.","year":"2009","unstructured":"Yang J.G.; Sun N.X.; Cui L.J.; Wang X.H.; Feng Z.H.; Adenovirus-mediated delivery of p27(KIP1) to prevent wound healing after experimental glaucoma filtration surgery. Acta Pharmacol Sin 2009,30(4),413-423","journal-title":"Acta Pharmacol Sin"},{"key":"ref=233","first-page":"32","volume":"8","author":"Vittitow J.L.","year":"2002","unstructured":"Vittitow J.L.; Garg R.; Rowlette L.L.; Epstein D.L.; O\u2019Brien E.T.; Borr&#xE1;s T.; Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis 2002,8,32-44","journal-title":"Mol Vis"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"118712","DOI":"10.1016\/j.lfs.2020.118712","volume":"264","author":"Naik S.","year":"2021","unstructured":"Naik S.; Shreya A.B.; Raychaudhuri R.; Pandey A.; Lewis S.A.; Hazarika M.; Bhandary S.V.; Rao B.S.S.; Mutalik S.; Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives. Life Sci 2021,264,118712","journal-title":"Life Sci"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1476-5381.2011.01586.x","volume":"165","author":"Martin-Gil A.","year":"2012","unstructured":"Martin-Gil A.; de Lara M.J.; Crooke A.; Santano C.; Peral A.; Pintor J.; Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits. Br J Pharmacol 2012,165(4b),1163-1172","journal-title":"Br J Pharmacol"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.optom.2017.08.002","volume":"11","author":"Loma P.","year":"2018","unstructured":"Loma P.; Guzman-Aranguez A.; de Lara M.J.P.; Pintor J.; Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits. J Optom 2018,11(2),69-74","journal-title":"J Optom"},{"key":"ref=237","first-page":"1","volume":"152","author":"Aktories K.","year":"2004","unstructured":"Aktories K.; Wilde C.; Vogelsgesang M.; Rho-modifying C3-like ADP-ribosyltransferases. Rev Physiol Biochem Pharmacol 2004,152,1-22","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.omtm.2019.11.017","volume":"17","author":"Tan J.","year":"2019","unstructured":"Tan J.; Wang X.; Cai S.; He F.; Zhang D.; Li D.; Zhu X.; Zhou L.; Fan N.; Liu X.; C3 Transferase-expressing scAAV2 transduces ocular anterior segment tissues and lowers intraocular pressure in mouse and monkey. Mol Ther Methods Clin Dev 2019,17,143-155","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.2015.0071","volume":"112","author":"Messmer E.M.","year":"2015","unstructured":"Messmer E.M.; The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015,112(5),71-81","journal-title":"Dtsch Arztebl Int"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.addr.2006.07.021","volume":"58","author":"Selvam S.","year":"2006","unstructured":"Selvam S.; Thomas P.B.; Hamm-Alvarez S.F.; Schechter J.E.; Stevenson D.; Mircheff A.K.; Trousdale M.D.; Current status of gene delivery and gene therapy in lacrimal gland using viral vectors. Adv Drug Deliv Rev 2006,58(11),1243-1257","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1740-2557-2-6","volume":"2","author":"Trousdale M.D.","year":"2005","unstructured":"Trousdale M.D.; Zhu Z.; Stevenson D.; Schechter J.E.; Ritter T.; Mircheff A.K.; Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J Autoimmune Dis 2005,2,6","journal-title":"J Autoimmune Dis"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1167\/iovs.10-5423","volume":"51","author":"Thomas P.B.","year":"2010","unstructured":"Thomas P.B.; Samant D.M.; Selvam S.; Wei R.H.; Wang Y.; Stevenson D.; Schechter J.E.; Apparailly F.; Mircheff A.K.; Trousdale M.D.; Adeno-associated virus-mediated IL-10 gene transfer suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Invest Ophthalmol Vis Sci 2010,51(10),5137-5144","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1073\/pnas.1601992113","volume":"113","author":"Lai Z.","year":"2016","unstructured":"Lai Z.; Yin H.; Cabrera-P&#xE9;rez J.; Guimaro M.C.; Afione S.; Michael D.G.; Glenton P.; Patel A.; Swaim W.D.; Zheng C.; Nguyen C.Q.; Nyberg F.; Chiorini J.A.; Aquaporin gene therapy corrects Sj&#xF6;gren\u2019s syndrome phenotype in mice. Proc Natl Acad Sci USA 2016,113(20),5694-5699","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-1-4615-5359-5_32","volume":"438","author":"Gipson I.K.","year":"1998","unstructured":"Gipson I.K.; Inatomi T.; Cellular origin of mucins of the ocular surface tear film. Adv Exp Med Biol 1998,438,221-227","journal-title":"Adv Exp Med Biol"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.1167\/iovs.11-7655","volume":"52","author":"Corrales R.M.","year":"2011","unstructured":"Corrales R.M.; Narayanan S.; Fern&#xE1;ndez I.; Mayo A.; Galarreta D.J.; Fuentes-P&#xE1;ez G.; Chaves F.J.; Herreras J.M.; Calonge M.; Ocular mucin gene expression levels as biomarkers for the diagnosis of dry eye syndrome. Invest Ophthalmol Vis Sci 2011,52(11),8363-8369","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=246","first-page":"1004","volume":"43","author":"Arg&#xFC;eso P.","year":"2002","unstructured":"Arg&#xFC;eso P.; Balaram M.; Spurr-Michaud S.; Keutmann H.T.; Dana M.R.; Gipson I.K.; Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sj&#xF6;gren syndrome. Invest Ophthalmol Vis Sci 2002,43(4),1004-1011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=247","first-page":"2483","volume":"42","author":"Kunert K.S.","year":"2001","unstructured":"Kunert K.S.; Keane-Myers A.M.; Spurr-Michaud S.; Tisdale A.S.; Gipson I.K.; Alteration in goblet cell numbers and mucin gene expression in a mouse model of allergic conjunctivitis. Invest Ophthalmol Vis Sci 2001,42(11),2483-2489","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/gt.2012.56","volume":"20","author":"Contreras-Ruiz L.","year":"2013","unstructured":"Contreras-Ruiz L.; Zorzi G.K.; Hileeto D.; L&#xF3;pez-Garc&#xED;a A.; Calonge M.; Seijo B.; S&#xE1;nchez A.; Diebold Y.; A nanomedicine to treat ocular surface inflammation: Performance on an experimental dry eye murine model. Gene Ther 2013,20(5),467-477","journal-title":"Gene Ther"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13052-018-0559-9","volume":"44","author":"Del Longo A.","year":"2018","unstructured":"Del Longo A.; Piozzi E.; Schweizer F.; Ocular features in mucopolysaccharidosis: Diagnosis and treatment. Ital J Pediatr 2018,44(Suppl. 2),125","journal-title":"Ital J Pediatr"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.eye.6701921","volume":"20","author":"Ashworth J.L.","year":"2006","unstructured":"Ashworth J.L.; Biswas S.; Wraith E.; Lloyd I.C.; The ocular features of the mucopolysaccharidoses. Eye (Lond) 2006,20(5),553-563","journal-title":"Eye (Lond)"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"Khan S.A.","year":"2017","unstructured":"Khan S.A.; Peracha H.; Ballhausen D.; Wiesbauer A.; Rohrbach M.; Gautschi M.; Mason R.W.; Giugliani R.; Suzuki Y.; Orii K.E.; Orii T.; Tomatsu S.; Epidemiology of mucopolysaccharidoses. Mol Genet Metab 2017,121(3),227-240","journal-title":"Mol Genet Metab"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1006\/mthe.2001.0461","volume":"4","author":"Kamata Y.","year":"2001","unstructured":"Kamata Y.; Okuyama T.; Kosuga M.; O\u2019hira A.; Kanaji A.; Sasaki K.; Yamada M.; Azuma N.; Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. Mol Ther 2001,4(4),307-312","journal-title":"Mol Ther"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2014.02.022","volume":"181","author":"Serratrice N.","year":"2014","unstructured":"Serratrice N.; Cubizolle A.; Ibanes S.; Mestre-Franc&#xE9;s N.; Bayo-Puxan N.; Creyssels S.; Gennetier A.; Bernex F.; Verdier J.M.; Haskins M.E.; Couderc G.; Malecaze F.; Kalatzis V.; Kremer E.J.; Corrective GUSB transfer to the canine mucopolysaccharidosis VII cornea using a helper-dependent canine adenovirus vector. J Control Release 2014,181,22-31","journal-title":"J Control Release"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/jovr.jovr_244_17","volume":"14","author":"Al-Rashidi S.H.","year":"2019","unstructured":"Al-Rashidi S.H.; Black diaphragm intraocular lens implantation in patients with aniridia. J Ophthalmic Vis Res 2019,14(1),27-31","journal-title":"J Ophthalmic Vis Res"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"108455","DOI":"10.1016\/j.exer.2021.108455","volume":"204","author":"Shah R.","year":"2021","unstructured":"Shah R.; Amador C.; Tormanen K.; Ghiam S.; Saghizadeh M.; Arumugaswami V.; Kumar A.; Kramerov A.A.; Ljubimov A.V.; Systemic diseases and the cornea. Exp Eye Res 2021,204,108455","journal-title":"Exp Eye Res"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s13353-017-0426-1","volume":"59","author":"Wawrocka A.","year":"2018","unstructured":"Wawrocka A.; Krawczynski M.R.; The genetics of aniridia - simple things become complicated. J Appl Genet 2018,59(2),151-159","journal-title":"J Appl Genet"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.omtm.2020.03.002","volume":"17","author":"Mirjalili Mohanna S.Z.","year":"2020","unstructured":"Mirjalili Mohanna S.Z.; Hickmott J.W.; Lam S.L.; Chiu N.Y.; Lengyell T.C.; Tam B.M.; Moritz O.L.; Simpson E.M.; Germline CRISPR\/Cas9-mediated gene editing prevents vision loss in a novel mouse model of aniridia. Mol Ther Methods Clin Dev 2020,17,478-490","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/stem.2858","volume":"36","author":"Roux L.N.","year":"2018","unstructured":"Roux L.N.; Petit I.; Domart R.; Concordet J.P.; Qu J.; Zhou H.; Joliot A.; Ferrigno O.; Aberdam D.; Modeling of aniridia-related keratopathy by CRISPR\/Cas9 genome editing of human limbal epithelial cells and rescue by recombinant PAX6 protein. Stem Cells 2018,36(9),1421-1429","journal-title":"Stem Cells"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523221666210423084233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/192991\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523221666210423084233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T14:04:57Z","timestamp":1724940297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/192991\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":258,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523221666210423084233","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}